Eva Novotná

1.4k total citations
78 papers, 1.1k citations indexed

About

Eva Novotná is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Eva Novotná has authored 78 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Molecular Biology, 26 papers in Organic Chemistry and 18 papers in Oncology. Recurrent topics in Eva Novotná's work include Cancer therapeutics and mechanisms (13 papers), Synthesis and biological activity (12 papers) and Aldose Reductase and Taurine (11 papers). Eva Novotná is often cited by papers focused on Cancer therapeutics and mechanisms (13 papers), Synthesis and biological activity (12 papers) and Aldose Reductase and Taurine (11 papers). Eva Novotná collaborates with scholars based in Czechia, Germany and Russia. Eva Novotná's co-authors include Vladimı́r Wsól, Jakub Hofman, František Malíř, Vladimír Ostrý, Jiřina Stolaříková, Jarmila Vinšová, Martin Krátký, Annie Pfohl‐Leszkowicz, František Trejtnar and H. Kresse and has published in prestigious journals such as SHILAP Revista de lepidopterología, International Journal of Molecular Sciences and Molecules.

In The Last Decade

Eva Novotná

78 papers receiving 1.1k citations

Peers

Eva Novotná

ONCOL

Wenqiang Cao China

Anna Ramunno Italy

Yung-Chi Cheng United States

Dejan Baskić Serbia

Chung Chui Hong Kong

Gopal Chakrabarti India

Karin Fritz‐Wolf Germany

Tamer M. Abdelghany Egypt

S.K. Puri India

Xiaohui Du China

Wenqiang Cao China

Eva Novotná

789 ×1.8

321 ×1.0

428 ×2.0

ONCOL

76 ×0.5

28 ×0.2

Citations per year, relative to Eva Novotná Eva Novotná (= 1×) peers Wenqiang Cao

Countries citing papers authored by Eva Novotná

Since Specialization

Citations

This map shows the geographic impact of Eva Novotná's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Novotná with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Novotná more than expected).

Fields of papers citing papers by Eva Novotná

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Novotná. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Novotná. The network helps show where Eva Novotná may publish in the future.

Co-authorship network of co-authors of Eva Novotná

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Novotná. A scholar is included among the top collaborators of Eva Novotná based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Novotná. Eva Novotná is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Watt, Torquil, et al.. (2023). The Impact of Subclinical Hypothyroidism on the Quality of Life During Pregnancy: Mapping 5-Level Version of EQ-5D and ThyPRO-39. Value in Health. 26(7). 1085–1097. 1 indexed citations

Novotná, Eva, et al.. (2022). Rapid Progression of COVID-19-Associated Fatal Capillary Leak Syndrome. Infectious Disease Reports. 14(6). 884–888. 5 indexed citations

Morell, A, Yu Zhang, Eva Novotná, et al.. (2022). Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters. Archives of Toxicology. 96(12). 3265–3277. 7 indexed citations

Morell, A, Eva Novotná, František Štaud, et al.. (2020). Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors. Cancers. 12(6). 1596–1596. 18 indexed citations

Novotná, Eva, Adam Skarka, Sarah Kammerer, et al.. (2020). Ensartinib (X-396) Effectively Modulates Pharmacokinetic Resistance Mediated by ABCB1 and ABCG2 Drug Efflux Transporters and CYP3A4 Biotransformation Enzyme. Cancers. 12(4). 813–813. 22 indexed citations

Hofman, Jakub, Eva Novotná, Sarah Kammerer, et al.. (2019). Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance. Drug Metabolism and Disposition. 47(7). 699–709. 18 indexed citations

Novotná, Eva, Jakub Hofman, A Morell, et al.. (2019). Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters. Biochemical Pharmacology. 163. 290–298. 12 indexed citations

Novotná, Eva, et al.. (2019). Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3. Chemico-Biological Interactions. 302. 101–107. 14 indexed citations

Kuča, Kamil, Jana Žďárová Karasová, Ondřej Soukup, et al.. (2018). Development of small bisquaternary cholinesterase inhibitors as drugs for pre-treatment of nerve agent poisonings. Drug Design Development and Therapy. Volume 12. 505–512. 5 indexed citations

10.

Andrýs, Rudolf, Marc Meier, Gabriele Möller, et al.. (2018). Initial characterization of human DHRS1 (SDR19C1), a member of the short-chain dehydrogenase/reductase superfamily. The Journal of Steroid Biochemistry and Molecular Biology. 185. 80–89. 5 indexed citations

11.

Krátký, Martin, et al.. (2014). Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates. Bioorganic & Medicinal Chemistry. 22(15). 4073–4082. 29 indexed citations

12.

Novotná, Eva, Aleš Tichý, Jaroslav Pejchal, et al.. (2013). DNA-dependent protein kinase and its inhibition in support of radiotherapy. International Journal of Radiation Biology. 89(6). 416–423. 11 indexed citations

13.

Vávrová, Jiřina, Emı́lie Lukášová, Martina Řezáčová, et al.. (2013). Inhibition of ATR kinase with the selective inhibitor VE-821 results in radiosensitization of cells of promyelocytic leukaemia (HL-60). Radiation and Environmental Biophysics. 52(4). 471–479. 30 indexed citations

14.

Šalovská, Barbora, Aleš Tichý, Martina Řezáčová, Jiřina Vávrová, & Eva Novotná. (2012). Enrichment strategies for phosphoproteomics: state-of-the-art. SHILAP Revista de lepidopterología. 31(1). 29–41. 9 indexed citations

15.

Pejchal, Jaroslav, Jan Österreicher, Aleš Tichý, et al.. (2012). Activation of p38 MAPK and expression of TGF-β1 in rat colon enterocytes after whole body γ-irradiation. International Journal of Radiation Biology. 88(4). 348–358. 21 indexed citations

16.

Novotná, Eva, Karel Waisser, Vladimı́r Buchta, Petr Jílek, & Marcela Vejsová. (2010). N-Benzylsalicylthioamides as novel compounds with promising antimycotic activity. Bioorganic & Medicinal Chemistry Letters. 20(15). 4535–4538. 3 indexed citations

17.

Novotná, Eva, et al.. (2010). Highly active antimycobacterial derivatives of benzoxazine. Bioorganic & Medicinal Chemistry. 18(23). 8178–8187. 33 indexed citations

18.

Brabcová, Irena, Vladimı́r Tesař, E Honsová, et al.. (2010). Association of advanced vasculopathy and transforming growth factor-beta1 gene expression with immunoglobulin A nephropathy progression. Nephrology Dialysis Transplantation. 26(2). 573–579. 13 indexed citations

19.

Waisser, Karel, Eva Novotná, Věra Klimešová, et al.. (2010). A note to the biological activity of benzoxazine derivatives containing the thioxo group. European Journal of Medicinal Chemistry. 45(7). 2719–2725. 26 indexed citations

20.

Pokorný, J., et al.. (1985). Reactions of oxidized lipids with protein. Part 13. Autoxidation of hexanal in presence of nonlipidic components. Food / Nahrung. 29(5). 459–465. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact